Rafferty Asset Management
CORT icon

Rafferty Asset Management’s Corcept Therapeutics CORT Stock Holding History

Rafferty Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221K Buy
+2,543
New +$154K ﹤0.01% 1079
2025
Q4 		– Sell
-3,019
Closed -$251K – 1139
2025
Q3 		$251K Sell
3,019
-317
-10% -$22.9K ﹤0.01% 1027
2025
Q2 		$245K Sell
3,336
-2,591
-44% -$188K ﹤0.01% 1017
2025
Q1 		$677K Buy
5,927
+21
+0.4% +$1.28K ﹤0.01% 815
2024
Q4 		$298K Sell
5,906
-5,606
-49% -$294K ﹤0.01% 1026
2024
Q3 		$533K Buy
11,512
+69
+0.6% +$2.45K ﹤0.01% 920
2024
Q2 		$372K Sell
11,443
-4,117
-26% -$113K ﹤0.01% 1021
2024
Q1 		$392K Buy
15,560
+7,151
+85% +$169K ﹤0.01% 1019
2023
Q4 		$273K Buy
+8,409
New +$231K ﹤0.01% 1040
2022
Q4 		– Sell
-8,637
Closed -$221K – 1130
2022
Q3 		$221K Sell
8,637
-2,434
-22% -$65.1K ﹤0.01% 1078
2022
Q2 		$263K Buy
+11,071
New +$241K ﹤0.01% 960
2022
Q1 		– Sell
-10,913
Closed -$216K – 1234
2021
Q4 		$216K Buy
+10,913
New +$221K ﹤0.01% 1212
2021
Q1 		– Sell
-10,110
Closed -$264K – 1162
2020
Q4 		$264K Buy
+10,110
New +$213K ﹤0.01% 871
2020
Q3 		– Sell
-12,185
Closed -$205K – 965
2020
Q2 		$205K Buy
+12,185
New +$171K ﹤0.01% 924
2019
Q3 		– Sell
-25,568
Closed -$285K – 810
2019
Q2 		$285K Sell
25,568
-23,237
-48% -$259K 0.01% 754
2019
Q1 		$573K Buy
+48,805
New +$606K 0.01% 642
2018
Q2 		– Sell
-59,201
Closed -$974K – 660
2018
Q1 		$974K Buy
+59,201
New +$1.1M 0.01% 464

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's CORT Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,543 shares worth $221K. The stake represents ﹤0.01% of the portfolio and ranks #1079 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in CORT as recently as Q3 2025.

Rafferty Asset Management first reported a position in CORT in Q1 2018 and has held it in 17 quarters since. The position peaked at $974K in Q1 2018. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Rafferty Asset Management held 2,543 shares of Corcept Therapeutics worth $221K as of Q2 2026.
  • Corcept Therapeutics was a new Rafferty Asset Management position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1079 holding.
  • Rafferty Asset Management first reported a position in Corcept Therapeutics in Q1 2018 and has held it in 17 quarters since.
  • Rafferty Asset Management's Corcept Therapeutics position peaked at $974K in Q1 2018.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.